Financing ·
On August 4, 2026, AbbVie Inc. entered into an underwriting agreement to issue and sell $9.5 billion in aggregate…
ABBVAbbVie Inc.
On August 4, 2026, AbbVie Inc. entered into an underwriting agreement to issue and sell $9.5 billion in aggregate principal amount of senior notes across multiple maturities ranging from 2028 to 2066. The offering includes floating rate notes due 2028, fixed-rate notes due 2028, 2030, 2031, 2033, 2036, 2038, 2056, and 2066. Net proceeds are expected to be approximately $9.93 billion after deducting underwriting discounts and offering expenses. AbbVie intends to use these funds to finance a portion of its cash payment obligations for the acquisition of Apogee Therapeutics, Inc., pay related fees and expenses, and reduce commitments under its $10.0 billion 364-day delayed draw term loan facility associated with that transaction. The closing is expected on August 18, 2026. AbbVie operates in the pharmaceutical industry, developing and commercializing innovative medicines.